These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
15. Liver Toxicity with Cancer Checkpoint Inhibitor Therapy. Nadeau BA; Fecher LA; Owens SR; Razumilava N Semin Liver Dis; 2018 Nov; 38(4):366-378. PubMed ID: 30357774 [TBL] [Abstract][Full Text] [Related]
16. [Immunotherapy is cancer treatment with a novel side-effect profile]. Kondrup M; Raunkilde L; Svane IM; Schmidt H; Bastholt L Ugeskr Laeger; 2017 Oct; 179(40):. PubMed ID: 28992844 [TBL] [Abstract][Full Text] [Related]
17. Significance of Immune-related Lipase Increase Induced by Antiprogrammed Death-1 or Death Ligand-1 Antibodies: A Brief Communication. Michot JM; Ragou P; Carbonnel F; Champiat S; Voisin AL; Mateus C; Lambotte O; Annereau M J Immunother; 2018; 41(2):84-85. PubMed ID: 29252914 [TBL] [Abstract][Full Text] [Related]
18. Diagnosis and Management of Immune Checkpoint Inhibitor-related Toxicities in Ovarian Cancer: A Series of Case Vignettes. Johnson C; Jazaeri AA Clin Ther; 2018 Mar; 40(3):389-394. PubMed ID: 29519715 [TBL] [Abstract][Full Text] [Related]
19. [Physiopathological mechanisms of immune-related adverse events induced by anti-CTLA-4, anti-PD-1 and anti-PD-L1 antibodies in cancer treatment]. Passat T; Touchefeu Y; Gervois N; Jarry A; Bossard C; Bennouna J Bull Cancer; 2018 Nov; 105(11):1033-1041. PubMed ID: 30244981 [TBL] [Abstract][Full Text] [Related]
20. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Boutros C; Tarhini A; Routier E; Lambotte O; Ladurie FL; Carbonnel F; Izzeddine H; Marabelle A; Champiat S; Berdelou A; Lanoy E; Texier M; Libenciuc C; Eggermont AM; Soria JC; Mateus C; Robert C Nat Rev Clin Oncol; 2016 Aug; 13(8):473-86. PubMed ID: 27141885 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]